Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED
██.█% Sign up free to reveal

Cytosorbents Corp (CTSO) AI Forecast

Our AI detected a significant signal for Cytosorbents Corp. Create a free account to see the exact price target.

Free account • 30-day free trial

$CTSO Bullish Signal Full forecast available

Cytosorbents Corp (CTSO) AI Stock Price Forecast & Investment Analysis

Cytosorbents Corp Stock Price Chart and Technical Analysis

Loading chart...

Cytosorbents Corp (CTSO) - Comprehensive Stock Analysis & Investment Research

Deep dive into Cytosorbents Corp's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on April 4, 2026, 7:36 a.m. (UTC)

Cytosorbents Corp Investment Summary

When evaluating whether Cytosorbents Corp (CTSO) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Cytosorbents Corp (CTSO) operates within the Industrial Applications and Services sector, specifically in the Surgical & Medical Instruments & Apparatus industry. The company employs approximately 176 people. With a market capitalization of $34 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Cytosorbents Corp's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Cytosorbents Corp along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Cytosorbents Corp is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Cytosorbents Corp

Sign Up Free
Corporate Identity

Cytosorbents Corp (Stock Symbol: CTSO) is a prominent company operating within the Industrial Applications and Services sector, with a specific focus on the Surgical & Medical Instruments & Apparatus industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Cytosorbents Corp's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Cytosorbents Corp...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Cytosorbents Corp...

Unlock Full Company Profile

Get complete details about Cytosorbents Corp

Sign Up Free
Revenue & Growth Analysis

Cytosorbents Corp generates annual revenues of $37 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Cytosorbents Corp...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Cytosorbents Corp...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Cytosorbents Corp...

Unlock Financial Analysis

Get complete financial metrics for Cytosorbents Corp

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Cytosorbents Corp's AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial

30-day free trial • Cancel anytime

Strategic Market Position

Cytosorbents Corp strategically competes in the highly dynamic Surgical & Medical Instruments & Apparatus marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Cytosorbents Corp competes within the Industrial Applications and Services sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-24 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Margin & Pricing Power Analysis

The company maintains a 455.9% gross margin which reflects exceptional pricing power and/or an asset-light business model. Gross margins at this level are typically seen in software, pharmaceuticals, or luxury goods companies where the cost of incremental production is minimal relative to selling prices. Such margins indicate significant competitive advantages protecting the company from price-based competition.

Operating margin of -426.6% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.

Asset Utilization Efficiency

Asset turnover ratio of 0.48x indicates moderate asset turnover common in capital-intensive industries such as utilities, real estate, or heavy manufacturing. Lower turnover in these sectors is expected due to the significant infrastructure required for operations.

Financial Strength & Leverage

Current ratio of 3.81 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Cytosorbents Corp (CTSO) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Cytosorbents Corp stock analysis.

Deep dive into Cytosorbents Corp's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Cytosorbents Corp stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Cytosorbents Corp: With a P/E ratio of -1.75, the market sees the stock as potentially undervalued.

P/E Ratio -1.75x
P/B Ratio 5.82x
Market Cap $34M
EPS $-0.45
Book Value/Share $0.09
Revenue/Share $0.59
FCF/Share $-0.29
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Cytosorbents Corp converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Cytosorbents Corp: An ROE of -44.3% indicates room for improvement in shareholder value creation.

ROE -44.3%
ROA -34.4%
ROIC -39.9%
Gross Margin 455.9%
Operating Margin -426.6%
Net Margin -359.6%
EBT Margin -73.5%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Cytosorbents Corp's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Cytosorbents Corp: A current ratio of 3.81 indicates strong liquidity.

Current Ratio 3.81x
Quick Ratio 3.24x
D/E Ratio 0.24x
Financial Leverage 1.50x
Interest Coverage -6.5x
Working Capital $72M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Cytosorbents Corp's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Cytosorbents Corp: Free cash flow of $-24M indicates cash challenges that need attention.

Operating Cash Flow -$20M
Free Cash Flow -$24M
Capital Spending -$5M
FCF/Sales -59.4%
CapEx/Sales 11.1%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Cytosorbents Corp uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Cytosorbents Corp: An asset turnover of 0.48x suggests room for improvement in asset utilization.

Asset Turnover 0.48x
Receivables Turnover 8.5x
Inventory Turnover 2.5x
Fixed Assets Turnover 3.4x
Days Sales Outstanding 43 days
Days Inventory 148 days
Payables Period 112 days
Cash Conversion Cycle 78 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Cytosorbents Corp's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Cytosorbents Corp: With annual revenue of $37M, Cytosorbents Corp represents a smaller but potentially high-growth operation.

Income Statement
Total Revenue $37M
Net Income -$324M
R&D Expense $198M
SG&A Expense $98M
Cost of Goods Sold $2M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 67%
Cash & Short-term Investments 52%
Total Liabilities 33%
Short-term Debt 6%
Accounts Receivable 6%
Inventory 7%
Dividend & Shareholder Information
Shares Outstanding 63M
Growth Metrics (YoY)
EPS Growth -51.1%

Latest Cytosorbents Corp Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Cytosorbents Corp (CTSO) stock price and investment outlook.

More news available

Sign up free to read all 12 news articles and stay updated on market developments.

Sign Up Free to Read More

Cytosorbents Corp Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of Cytosorbents Corp against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Adagio Medical Holdings, Inc. ADGM ██% $27M x 2.2x
Aethlon Medical Inc AEMD ██% $3M -0.1x 0.5x
Acutus Medical, Inc. AFIB ██% $0.00M 0.0x -0.4x
Allurion Technologies, Inc. ALUR ██% $12M -0.4x -0.3x
Autonomix Medical, Inc. AMIX ██% $4M x 0.5x
Angiodynamics Inc ANGO ██% $430M -1.4x 2.5x
Anika Therapeutics, Inc. ANIK ██% $209M -4.3x 1.5x
Artivion, Inc. AORT ██% $1.55B 158.6x 3.5x
Apyx Medical Corp APYX ██% $153M -3.5x 10.5x
Accuray Inc ARAY ██% $46M 4.5x 0.7x
Alphatec Holdings, Inc. ATEC ██% $1.68B -7.4x 135.3x
Atricure, Inc. ATRC ██% $1.42B -39.6x 2.9x
Nuo Therapeutics, Inc. AURX ██% $75M x 77.9x
Avita Medical, Inc. AVHHL ██% $22M x x
Baxter International Inc BAX ██% $8.61B -94.9x 1.4x
Beta Bionics, Inc. BBNX ██% $450M x 1.6x
Becton Dickinson & Co BDX ██% $56.54B 32.2x 2.2x
Heartbeam, Inc. BEAT ██% $50M -5.7x 19.3x
Bluejay Diagnostics, Inc. BJDX ██% $2M -0.5x 0.3x
Boston Scientific Corp BSX ██% $91.78B 31.7x 3.8x
Biotricity Inc. BTCY ██% $7M -2.7x 2.5x
Bioventus Inc. BVS ██% $610M 26.8x 3.3x
Brainsway Ltd. BWAY ██% $537M x x
Carlsmed, Inc. CARL ██% $256M x 2.6x
Cerus Corp CERS ██% $359M -13.8x 5.6x
Clearpoint Neuro, Inc. CLPT ██% $272M -23.5x 9.7x
Co-Diagnostics, Inc. CODX ██% $3M -0.7x 0.2x
Cytosorbents Corp CTSO ██% $34M -1.8x 5.8x
Cvrx, Inc. CVRX ██% $236M -5.5x 6.0x
Delcath Systems, Inc. DCTH ██% $334M 123.7x 3.0x
Dih Holding Us, Inc. DHAI ██% $70K x -0.3x
Dariohealth Corp. DRIO ██% $56M 0.6x 0.8x
Alpha Tau Medical Ltd. DRTS ██% $621M x 8.1x
Dexcom Inc DXCM ██% $23.94B 28.6x 8.7x
Dynatronics Corp DYNT ██% $540K -0.2x 0.2x
Ebr Systems, Inc. EBRCZ ██% $215M x 8.4x
Encision Inc ECIA ██% $2M x 1.2x
Embecta Corp. EMBC ██% $520M 3.7x -0.8x
Electromedical Technologies, Inc EMED ██% $750K x x
Femasys Inc FEMY ██% $25M -1.4x 4.2x
Family Office Of America, Inc. FOFA ██% $48M x 59.5x
Glucotrack, Inc. GCTK ██% $720K 0.9x 0.3x
Global Innovative Platforms Inc. GIPL ██% $320K x 2.0x
Glaukos Corp GKOS ██% $6.48B -46.3x 9.9x
Globus Medical Inc GMED ██% $11.86B 22.1x 2.6x
Fractyl Health, Inc. GUTS ██% $71M x 7.5x
Haemonetics Corp HAE ██% $2.63B 15.0x 2.9x
Harvard Apparatus Regenerative Technology, Inc. HRGN ██% $29M x 27.9x
Heartflow, Inc. HTFL ██% $2.09B x 7.0x
Integra Lifesciences Holdings Corp IART ██% $734M 200.2x 0.7x
Icecure Medical Ltd. ICCM ██% $24M x 2.7x
Seastar Medical Holding Corp ICU ██% $88M -1.1x 7.7x
Icu Medical Inc/De ICUI ██% $3.09B 4223.3x 1.5x
Interpace Biosciences, Inc. IDXG ██% $56M 2.3x 2.5x
Inspira Technologies Oxy B.H.N. Ltd IINN ██% $20M x 8.5x
Inspira Technologies Oxy B.H.N. Ltd IINNW ██% $7M x 1.5x
Intelligent Bio Solutions Inc. INBS ██% $6M -0.3x 0.6x
Infusystem Holdings, Inc INFU ██% $169M 30.5x 3.0x
Inspire Medical Systems, Inc. INSP ██% $1.53B 10.5x 2.0x
Iradimed Corp IRMD ██% $1.23B 54.9x 13.0x
Irhythm Holdings, Inc. IRTC ██% $3.82B -20.2x 25.0x
Invo Fertility, Inc. IVF ██% $18M x 3.1x
Orthopediatrics Corp KIDS ██% $409M -20.7x 1.2x
Kestra Medical Technologies, Ltd. KMTS ██% $1.17B x 4.1x
Koru Medical Systems, Inc. KRMD ██% $198M -19.8x 11.6x
Lemaitre Vascular Inc LMAT ██% $2.48B 42.9x 6.3x
Lensar, Inc. LNSR ██% $72M -6.7x 14.7x
Lucid Diagnostics Inc. LUCD ██% $196M -0.6x 17.9x
Pulmonx Corp LUNG ██% $53M -4.3x 1.0x
Lyra Therapeutics, Inc. LYRA ██% $870K -0.1x 0.5x
Microbot Medical Inc. MBOT ██% $159M -1.3x 2.1x
Mountain Crest Acquisition Corp. V MCAG ██% $34M x 1509.8x
Mountain Crest Acquisition Corp. V MCAGU ██% $31M x -9.9x
Spectral Ai, Inc. MDAI ██% $44M -1.3x 30.8x
Medinotec Inc. MDNC ██% $59M 25.1x 10.7x
Mimedx Group, Inc. MDXG ██% $585M 12.0x 2.3x
Monogram Technologies Inc. MGRM ██% $217M -10.7x 25.1x
Meihua International Medical Technologies Co., Ltd. MHUA ██% $151M x 0.9x
3m Co MMM ██% $77.02B 23.7x 16.4x
Merit Medical Systems Inc MMSI ██% $4.05B 31.6x 2.6x
Modular Medical, Inc. MODD ██% $25M -2.1x 4.3x
Nephros Inc NEPH ██% $32M 26.4x 3.1x
Neuroone Medical Technologies Corp NMTC ██% $40M -1.7x 6.3x
Neuropace Inc NPCE ██% $492M -10.4x 25.9x
Inspiremd, Inc. NSPR ██% $68M -4.3x 1.2x
Nu-Med Plus, Inc. NUMD ██% $930K x 4.8x
Novocure Ltd NVCR ██% $1.18B -20.8x 3.5x
Envveno Medical Corp NVNO ██% $7M x 0.3x
Nexgel, Inc. NXGL ██% $5M -6.8x 1.1x
Nyxoah Sa NYXH ██% $136M x x
Orchestra Biomed Holdings, Inc. OBIO ██% $248M -3.4x 4.6x
Odyssey Health, Inc. ODYY ██% $6M x 0.8x
Orthofix Medical Inc. OFIX ██% $459M -5.8x 1.0x
Osr Holdings, Inc. OSRH ██% $16M x 0.2x
Orasure Technologies Inc OSUR ██% $215M 17.1x 0.6x
Pavmed Inc. PAVM ██% $15M 36.5x 0.4x
Pro Dex Inc PDEX ██% $164M 14.4x 3.9x
Penumbra Inc PEN ██% $12.90B 72.6x 9.0x
Petvivo Holdings, Inc. PETV ██% $24M -1.4x 7.1x
Profusa, Inc. PFSA ██% $790K x x
Polyrizon Ltd. PLRZ ██% $20M x 1.0x
Pulse Biosciences, Inc. PLSE ██% $1.56B -2.6x 19.4x
Picard Medical, Inc. PMI ██% $71M x 18.8x
Insulet Corp PODD ██% $14.57B 59.0x 9.6x
Procept Biorobotics Corp PRCT ██% $1.43B -45.4x 3.9x
Premier Air Charter Holdings Inc. PREM ██% $2M x 2.1x
Profound Medical Corp. PROF ██% $237M x 3.6x
Plus Therapeutics, Inc. PSTV ██% $28M -0.3x 7.1x
Polypid Ltd. PYPD ██% $80M x 7.3x
Avita Medical, Inc. RCEL ██% $115M -5.0x 25.2x
Vivos Inc RDGL ██% $41M x 24.6x
Resmed Inc RMD ██% $32.46B 21.9x 5.1x
Resmed Inc RSMDF ██% $3.82B 2.7x 0.6x
Retinalgenix Technologies Inc. RTGN ██% $60M x x
Retractable Technologies Inc RVP ██% $20M -0.9x 0.3x
Sight Sciences, Inc. SGHT ██% $196M -3.7x 3.1x
Si-Bone, Inc. SIBN ██% $568M -14.3x 3.2x
Sigyn Therapeutics, Inc. SIGY ██% $50K x 0.1x
Sintx Technologies, Inc. SINT ██% $10M x 3.4x
Beauty Health Co SKIN ██% $118M -1.8x 1.9x
Sonoma Pharmaceuticals, Inc. SNOA ██% $4M -5.6x 1.2x
Sanuwave Health, Inc. SNWV ██% $146M 12.4x 90.3x
Solventum Corp SOLV ██% $11.16B 7.2x 2.2x
Sensus Healthcare, Inc. SRTS ██% $68M 31.6x 1.4x
Ss Innovations International, Inc. SSII ██% $1.01B x 26.4x
Strata Skin Sciences, Inc. SSKN ██% $1M -8.0x 0.5x
Neuronetics, Inc. STIM ██% $103M -1.0x 4.6x
Stimcell Energetics Inc. STME ██% $7M x 1152.5x
Sharps Technology Inc. STSS ██% $47M -2.5x 0.2x
Stevanato Group S.P.A. STVN ██% $3.77B x x
Stryker Corp SYK ██% $125.90B 38.8x 5.6x
Tactile Systems Technology Inc TCMD ██% $552M 28.9x 2.5x
Tela Bio, Inc. TELA ██% $25M -1.8x 4.0x
Teleflex Inc TFX ██% $5.26B 31.0x 1.7x
Trisalus Life Sciences, Inc. TLSI ██% $260M -3.6x 28.5x
Trisalus Life Sciences, Inc. TLSIW ██% $62M x -1.9x
Treace Medical Concepts, Inc. TMCI ██% $89M -7.5x 1.0x
Tandem Diabetes Care Inc TNDM ██% $1.28B -17.1x 8.3x
Tenon Medical, Inc. TNON ██% $8M -0.3x 1.5x
T2 Biosystems, Inc. TTOO ██% $210K 0.0x -0.3x
Ufp Technologies Inc UFPT ██% $1.46B 21.4x 3.5x
Qhslab, Inc. USAQ ██% $9M 20.2x 5.7x
Utah Medical Products Inc UTMD ██% $200M 17.8x 1.7x
Venus Concept Inc. VERO ██% $560K 0.0x 0.2x
Catheter Precision, Inc. VTAK ██% $2M x 0.3x
Vivos Therapeutics, Inc. VVOS ██% $15M x 5.8x
Vycor Medical Inc VYCO ██% $3M x 36.9x
West Pharmaceutical Services Inc WST ██% $18.28B 37.0x 5.8x
Beyond Air, Inc. XAIR ██% $7M -0.3x 0.9x
Xtant Medical Holdings, Inc. XTNT ██% $72M 14.4x 1.4x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Cytosorbents Corp Stock Forecast

How accurate are Cytosorbents Corp stock predictions?

Our AI model shows a 1% Spearman correlation coefficient for CTSO predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Cytosorbents Corp stock price forecasts?

Our analysis considers Cytosorbents Corp's financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Cytosorbents Corp a good investment in 2025?

Based on our AI analysis, Cytosorbents Corp shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Cytosorbents Corp forecasts updated?

Cytosorbents Corp stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Cytosorbents Corp?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...